Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Nashville, Tennessee Clinical Trials

A listing of Nashville, Tennessee clinical trials actively recruiting patient volunteers.

RESULTS

Found (17) clinical trials

A Study Assessing the Safety Tolerability and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of RO7171009 administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) compared with sham control.

Phase

1.3 miles

Learn More »

Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

The IMC-C103C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable tumors of interest which include NSCLC, esophageal carcinoma, gastric carcinoma, HNSCC, and urothelial carcinoma and will be conducted in two phases. A Phase 1 dose escalation study to identify the MTD/RP2D of IMC-C103C as monotherapy (Arm A1) and ...

Phase

1.3 miles

Learn More »

MGD019 DART Protein in Unresectable/Metastatic Cancer

This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a 3+3+3 design in patients with advanced solid tumors of any histology. Once the MTD/MAD is determined, a Cohort Expansion Phase will be enrolled to further characterize ...

Phase

1.3 miles

Learn More »

Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies, who are ineligible for or there are no available therapies known to confer a clinical benefit for their ...

Phase

1.3 miles

Learn More »

AO-176 in Multiple Solid Tumor Malignancies

This study will examine AO-176 monotherapy in patients with select advanced solid tumors for which standard therapy proven to provide clinical benefit does not exist or is no longer effective. The study utilizes a classic 3+3 design, with enrollment of 3 patients per cohort and expansion of the cohort in ...

Phase

1.3 miles

Learn More »

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

The primary objective of the study is to collect long-term safety information on anetumab ravtansine and to enable patients, who received an anetumab ravtansine-containing treatment in any Bayer-sponsored anetumab ravtansine parent study, to continue the treatment. The secondary objective is to further investigate the efficacy of the drug.

Phase

1.3 miles

Learn More »

Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Adoptive T-cell therapy (ACT) is a therapeutic approach that uses T lymphocytes of subjects with cancer, obtained by leukapheresis with the aim of generating an anti-tumor T-cell immune response. NY-ESO-1 and LAGE-1a antigens are tumor-associated proteins that have been found in several tumor types. Clinical trials using ACT with T-cells ...

Phase

1.3 miles

Learn More »

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

This is a multicenter, open-label, sequential-cohort, dose-escalation Phase 1 study of PRT543 in patients with advanced cancers who have exhausted available treatment options. Enrollment will take place concurrently into two distinct patient groups (one for solid tumors/lymphomas and one for hematological malignancies). The study will consist of 2 parts, a ...

Phase

1.3 miles

Learn More »

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas. The study design consists of Dose Escalation and Dose Expansion Cohorts. In ...

Phase

1.3 miles

Learn More »

Pediatric Image-Guided Cochlear Implant Programming

Although children with cochlear implants (CIs) have significantly improved speech, language, and reading outcomes relative to previous generation CI recipients, too many pediatric CI users still display persistent speech, language, and reading difficulties despite early implantation and early intervention. Children with CIs typically lag behind their peers with normal hearing ...

Phase N/A

1.5 miles

Learn More »